Soticlestat (OV935/TAK-935)
Dravet Syndrome, Lennox-Gastaut Syndrome
Phase 3Licensed to Takeda
Key Facts
Indication
Dravet Syndrome, Lennox-Gastaut Syndrome
Phase
Phase 3
Status
Licensed to Takeda
Company
About Ovid Therapeutics
Ovid Therapeutics is a New York-based biotech dedicated to conquering rare neurological diseases through courageous science. Founded in 2014, the company has evolved its pipeline to focus on next-generation mechanisms for treatment-resistant seizures and neurodevelopmental disorders, including its lead GABA-AT inhibitor OV329 and KCC2 activator platform. While its former lead asset, soticlestat, is partnered with Takeda, Ovid is now advancing a wholly-owned, precision-focused pipeline for high-need patient communities with significant unmet medical need.
View full company profileTherapeutic Areas
Other Dravet Syndrome, Lennox-Gastaut Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Soticlestat (TAK-935) | Takeda Pharmaceutical | Phase 3 |